Author: Ravi Shankar

Dynamic Fleet Growth on Track

Five New-Technology Panamaxes on Order

Tanker Market Fundamentals Remain Strong

ATHENS, Greece, Sept. 28, 2026 (GLOBE NEWSWIRE) — TEN, Ltd. (NYSE: TEN) (the “Company”) today reported the sale of the oldest vessel in its fleet, the 2003 Japanese-built Panamax tanker Andes, to independent third parties. The sale generated approximately $13.0 million of free cash and registered a $4.6 million capital gain, to be recorded in the third quarter of 2026.  

“The Company has embarked on a significant fleet growth program, as reflected in its 26-vessel orderbook, of which seven vessels have already been delivered. Particular emphasis has been placed on the flexible Panamax segment through the construction of five units,” Mr. George Saroglou, President of TEN commented. “Looking ahead, we will continue to evaluate sale and purchase opportunities while remaining committed to maintaining fleet modernity and operational flexibility that have allowed TEN to thrive through market cycles over the decades,” Mr. Saroglou concluded.

TEN’s CURRENT NEWBUILDING PROGRAM

#	Name	Type	Delivery (exp)	Status	Employment
CONVENTIONAL TANKERS
1	DR IRENE TSAKOS	Suezmax – Scrubber Fitted	Q2 2025	DELIVERED	Yes
2	SILIA T	Suezmax – Scrubber Fitted	Q4 2025	DELIVERED	Yes
3	DELOS T	MR – Scrubber Fitted	Q1 2026	DELIVERED	Yes
4	DION	MR – Scrubber Fitted	Q1 2026	DELIVERED	Yes
5	AMAZONA	Panamax LR1 – Scrubber Fitted	Q2 2027	Under Construction	TBA
6	MAYA	Panamax LR1 – Scrubber Fitted	Q3 2027	Under Construction	TBA
7	INCA	Panamax LR1 – Scrubber Fitted	Q4 2027	Under Construction	TBA
8	CHAIRMAN DJS	VLCC – Scrubber Fitted	Q4 2027	Under Construction	TBA
9	TBN	VLCC – Scrubber Fitted	Q1 2028	Under Construction	TBA
10	TBN	VLCC – Scrubber Fitted	Q2 2028	Under Construction	TBA
11	AZTEC	Panamax LR1 – Scrubber Fitted	Q3 2028	Under Construction	TBA
12	ANDES	Panamax LR1 – Scrubber Fitted	Q3 2028	Under Construction	TBA
SHUTTLE TANKERS
13	ATHENS 04	DP2 Shuttle Tanker	Q2 2025	DELIVERED	Yes
14	PARIS 24	DP2 Shuttle Tanker	Q3 2025	DELIVERED	Yes
15	ANFIELD DP	DP2 Shuttle Tanker	Q3 2026	DELIVERED	Yes
16	ARIANO SUASSUNA DP	DP2 Shuttle Tanker	Q3 2027	Under Construction	Yes
17	ELZA SOARES DP	DP2 Shuttle Tanker	Q4 2027	Under Construction	Yes
18	MARIA FIRMINA DP	DP2 Shuttle Tanker	Q1 2028	Under Construction	Yes
19	CAROLINA DE JESUS DP	DP2 Shuttle Tanker	Q2 2028	Under Construction	Yes
20	DR SOCRATES DP	DP2 Shuttle Tanker	Q3 2028	Under Construction	Yes
21	MARACANA DP	DP2 Shuttle Tanker	Q3 2028	Under Construction	Yes
22	CORINTHIANS DP	DP2 Shuttle Tanker	Q4 2028	Under Construction	Yes
23	IPANEMAS DP	DP2 Shuttle Tanker	Q4 2028	Under Construction	Yes
24	COPA DP	DP2 Shuttle Tanker	Q4 2028	Under Construction	Yes
LNG CARRIERS
25	NY ENERGY 26	LNG Carrier	Q3 2028	Under Construction	TBA
26	TBN	LNG Carrier	Q1 2029	Under Construction	TBA

ABOUT TEN LTD.
Founded in Bermuda in 1993 and celebrating 33 years as a public company, 24 of which on the NYSE, TEN is one of the first and most established public shipping companies in the world. TEN’s diversified pro-forma energy fleet currently consists of 80 vessels, totaling approx. 10.4 million dwt.

ABOUT FORWARD-LOOKING STATEMENTS
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those predicted by such forward-looking statements. TEN undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Tsakos Energy Navigation Ltd.
George Saroglou
President & COO
+30210 94 07 710
gsaroglou@tenn.gr

Investor Relations / Media
Capital Link, Inc.
Nicolas Bornozis/ Markella Kara
+212 661 7566
ten@capitallink.com

Seasoned technology executive to lead Adeia’s continued growth; succeeds Paul E. Davis, who announced in May 2026 his intention to step down after 15 years with the company

SAN JOSE, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — Adeia Inc. (Nasdaq: ADEA), the technology company pioneering foundational innovations that shape how the world computes, connects, and experiences entertainment, today announced that its board of directors (the “Board”) has appointed Dipti Vachani as chief executive officer, effective October 12, 2026. Vachani will also join the Board, effective the same day. She succeeds Paul E. Davis, who in May 2026 informed the company of his intention to step down as chief executive officer and member of the Board to focus on his health and personal pursuits. Davis has agreed to serve in an advisory capacity through the end of the year to support a smooth transition.

Vachani brings to Adeia a tremendous wealth of broad leadership experience, technical credibility and meaningful partnerships, developed over nearly 30 years in the semiconductor industry. She has deep expertise in semiconductor ecosystems, advanced computer architectures, AI infrastructure, and long-cycle commercial relationships with demonstrated success expanding global businesses into new sectors.

Vachani most recently served as senior vice president, general manager, Automotive Business Unit for Arm Limited, a position she held from 2018 until 2026, where she successfully developed market specific IP programs into new, high-value recurring revenue streams. She also helped develop Arm Total Access and Arm Flexible Access, expanding IP utilization across the licensee base, and founded the SOAFEE Alliance, which today includes more than 200 member companies. From 2015 to 2018, Vachani was vice president, general manager of Intel Corporation’s Internet of Things Group. Prior to Intel, Vachani was vice president, general manager, Power, Lighting and Display at Skyworks Solutions beginning in 2013. Before Skyworks, Vachani held various program and product line positions at Texas Instruments, Inc. ending as vice president, general manager, Single Core Processors.

Vachani served as a member of the board of directors of Axcelis Technologies, Inc., a publicly traded semiconductor equipment manufacturer, from 2022 to 2025. Vachani earned a Bachelor of Science degree in Computer Engineering from Texas A&M University and an Executive M.B.A. from The University of Texas at Austin.

The Board selected Vachani for her proven track record and commitment to innovation to build upon Adeia’s successful transformation. She will continue the focus on strengthening our technology leadership in the semiconductor and media markets, diversifying our recurring revenue streams beyond Pay-TV, identifying and investing in new growth areas, and fostering a culture that empowers our people to achieve the company’s long-term value creation goals.

“Dipti Vachani is the right leader for Adeia’s next chapter,” said Dan Moloney, chairman of the Board. “The Board’s Transition Committee conducted a rigorous search process and considered an exceptional field of candidates, and Vachani stood out for her ability to translate R&D capabilities and innovation roadmap into greater strategic relevance, new markets, stronger customer and ecosystem pull, and ultimately greater shareholder value. Our business today is positioned for continued revenue growth, led by an exceptional executive team with decades of experience and past successes. On behalf of the entire Board, I also want to thank Paul for four years of exceptional leadership and guidance; he leaves the company in a position of significant financial and strategic strength.”

“It is an honor to be chosen to lead Adeia,” said Dipti Vachani. “Adeia’s award-winning portfolio of more than 14,250 worldwide patent assets, its deep culture of invention, and the momentum the team has built provide a remarkable foundation for the company’s future. The opportunities ahead are extraordinary, from hybrid bonding and advanced thermal solutions for the AI-driven semiconductor ecosystem to new licensing frontiers across streaming, e-commerce, and automotive. I look forward to working with Adeia’s talented inventors and employees to deliver long-term value for our customers, partners, and shareholders.”

“Leading Adeia has been the greatest honor of my career, and I could not be more confident in where the company goes from here,” said Davis. “Vachani brings strong leadership experience and a history of driving growth at technology companies. With diversified revenue streams, a strengthened balance sheet, and growing opportunities in both our media and semiconductor businesses, Adeia’s future is as promising as it has ever been. I want to thank our dedicated employees and the Board, and I look forward to supporting a seamless transition.”

About Adeia 

Adeia Inc. (Nasdaq: ADEA) develops foundational innovations that shape how the world computes, connects and experiences entertainment. Its inventions span a broad range of semiconductor and media technologies, including 3D interconnect (hybrid bonding) and advanced thermal management for AI datacenters, as well as content discovery, personalization, and streaming. These inventions are licensed to leaders across the chip design and manufacturing, consumer electronics, automotive, digital entertainment, and e-commerce industries. Adeia’s innovations enable more powerful and efficient products, and more immersive, personalized experiences across billions of devices worldwide. Learn more at www.adeia.com. 

Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements are based on information available to the Company as of the date hereof, as well as the Company’s current expectations, assumptions, estimates and projections that involve risks and uncertainties. In this context, forward-looking statements often address expected future business, financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “could,” “seek,” “see,” “will,” “may,” “would,” “might,” “potentially,” “estimate,” “continue,” “target,” similar expressions or the negatives of these words or other comparable terminology that convey uncertainty of future events or outcomes. All forward-looking statements by their nature address matters that involve risks and uncertainties, many of which are beyond the Company’s control, and are not guarantees of future results.

Forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements. Important risk factors that may cause such a difference include, but are not limited to: the Company’s ability to implement its business strategy; the Company’s ability to enter into new and renewal license agreements with customers on favorable terms; the Company’s ability to retain and hire key personnel; uncertainty as to the long-term value of the Company’s common stock; legislative, regulatory and economic developments affecting the Company’s business; general economic and market developments and conditions; the Company’s ability to grow and expand its patent portfolios; changes in technology and development of new technology in the industries in which the Company operates; the evolving legal, regulatory and tax regimes under which the Company operates; unforeseen liabilities and expenses; risks associated with the Company’s indebtedness; and the unpredictability and severity of catastrophic events. These risks, as well as other risks associated with the Company’s business, are more fully discussed in the Company’s filings with the U.S. Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws.

Contacts

Adeia Investor Relations
Chris Chaney
IR@adeia.com

Adeia Media Relations
Anna Enerio
marketing@adeia.com

Acquisition brings leading AI model research expertise to AMD, helping to shape future AI infrastructure and strengthen the open AI ecosystem

SANTA CLARA, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) — AMD (NASDAQ: AMD) today announced that it has entered into a definitive agreement to acquire World Labs, an AI model and research lab led by AI pioneer Dr. Fei-Fei Li. The acquisition will bring a world-class team of researchers and model experts to AMD, strengthening its ability to develop AI hardware, software and systems around the needs of emerging models and applications.

As AI expands into reasoning, robotics, simulation and physical AI, the demands on compute infrastructure become more diverse. World Labs’ expertise in developing advanced models will give AMD deeper insight into how workloads are evolving and help shape its future technology roadmaps. The acquisition advances AMD’s strategy to deliver AI infrastructure for an open ecosystem.

“Building the compute platforms for the next generation of AI requires a deep understanding of how models are evolving,” said Dr. Lisa Su, chair and CEO, AMD. “Fei-Fei and the World Labs team bring exceptional research leadership and model expertise. Together, we can use that insight to develop the hardware, software and systems that will power the next generation of AI and strengthen the open AI ecosystem.”

“Advancing the next generation of AI technology requires close collaboration across model research, systems and compute,” said Dr. Fei-Fei Li, co-founder and CEO, World Labs. “Joining AMD will give our team the resources and engineering depth to accelerate our research and help define the infrastructure needed for the next era of AI.”

Headquartered in San Francisco, World Labs develops spatial-intelligence models that generate, reconstruct and simulate interactive 3D environments from text, image and video inputs, as well as technology for robotic learning and simulation. Following the close of the transaction, the World Labs team will continue to focus on advancing AI model research, and Dr. Fei-Fei Li will join AMD as executive vice president and chief scientist, reporting to Dr. Lisa Su.

The all-stock transaction is valued at approximately $8.2 billion and is expected to close by the end of 2026, subject to regulatory approvals and other customary closing conditions.

About AMD  
AMD (NASDAQ: AMD) drives innovation in high-performance and AI computing to solve the world’s most important challenges. Today, AMD technology powers billions of experiences across cloud and AI infrastructure, embedded systems, AI PCs and gaming. With a broad portfolio of AI-optimized CPUs, GPUs, networking and software, AMD delivers full-stack AI solutions that provide the performance and scalability needed for a new era of intelligent computing. Learn more at www.amd.com.  

CAUTIONARY STATEMENT
This press release contains forward-looking statements concerning Advanced Micro Devices, Inc. (AMD) such as the anticipated benefits from the acquisition of World Labs by AMD and the expected timing of the closing of the acquisition, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as “would,” “may,” “expects,” “believes,” “plans,” “intends,” “projects” and other terms with similar meaning. Investors are cautioned that the forward-looking statements in this press release are based on current beliefs, assumptions and expectations, speak only as of the date of this press release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. Such statements are subject to certain known and unknown risks and uncertainties, many of which are difficult to predict and are generally beyond AMD’s control, that could cause actual results and other future events to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. Material factors that could cause actual results to differ materially from current expectations include, without limitation, the following: impact of government actions and regulations such as export regulations, national-security-based regulations, import tariffs, trade protection measures, and licensing requirements; competitive markets in which AMD’s products are sold; the cyclical nature of the semiconductor industry; market conditions of the industries in which AMD products are sold; AMD’s ability to introduce products on a timely basis with expected features and performance levels; loss of a significant customer; economic and market uncertainty; quarterly and seasonal sales patterns; AMD’s ability to adequately protect its technology or other intellectual property; unfavorable currency exchange rate fluctuations; ability of third party manufacturers to manufacture AMD’s products on a timely basis in sufficient quantities and using competitive technologies; availability of essential equipment, materials, components (such as memory supply), substrates or manufacturing processes; ability to achieve expected manufacturing yields for AMD’s products; AMD’s ability to generate revenue from its semi-custom SoC products; potential security vulnerabilities; potential security incidents including IT outages, data loss, data breaches and cyberattacks; uncertainties involving the ordering and shipment of AMD’s products; AMD’s reliance on third-party intellectual property to design and introduce new products; AMD’s reliance on third-party companies for design, manufacture and supply of motherboards, software, memory and other computer platform components; AMD’s reliance on Microsoft and other software vendors’ support to design and develop software to run on AMD’s products; AMD’s reliance on third-party distributors and add-in-board partners; impact of modification or interruption of AMD’s internal business processes and information systems; compatibility of AMD’s products with some or all industry-standard software and hardware; costs related to defective products; failure to maintain an efficient supply chain as customer demand changes; AMD’s ability to rely on third party supply-chain logistics functions; AMD’s ability to effectively control sales of its products on the gray market; impact of climate change on AMD’s business; AMD’s ability to realize its deferred tax assets; potential tax liabilities; current and future claims and litigation; impact of environmental laws, conflict minerals related provisions and other laws or regulations; evolving expectations from governments, investors, customers and other stakeholders regarding corporate responsibility matters; issues related to the responsible use of AI; restrictions imposed by agreements governing AMD’s notes, the guarantees of Xilinx’s notes and the revolving credit agreement; AMD’s ability to satisfy financial obligations under guarantees, leases and other commercial commitments; impact of acquisitions, joint ventures and/or investments on AMD’s business and AMD’s ability to integrate acquired businesses; impact of any impairment of the combined company’s assets; political, legal and economic risks and natural disasters; future impairments of technology license purchases; AMD’s ability to attract and retain key employees; and AMD’s stock price volatility. Investors are urged to review in detail the risks and uncertainties in AMD’s Securities and Exchange Commission filings, including but not limited to AMD’s most recent reports on Forms 10-K and 10-Q.

Contact
Brandi Martina
AMD Communications
corporate.pressinquiry@amd.com

Liz Stine
AMD Investor Relations
investor.relations@amd.com

XIAMEN, Sept. 28, 2026 (GLOBE NEWSWIRE) — STAR FASHION CULTURE HOLDINGS LIMITED (NASDAQ: STFS) (the “Company” or “STFS”) today announced the Closing of its best-efforts follow-on public offering on September 28, 2026 of 12,000,000 Class A ordinary shares at a public offering price of $0.80 per Class A ordinary share (the “Offering”).

Gross proceeds, before deducting placement agent fees and other offering expenses, are expected to be approximately $9,600,000. The Company intends to use the net proceeds of this offering for developing its online marketing services and for general administration and working capital.

Kingswood Capital Partners, LLC acted as the placement agent (the “Placement Agents”) in connection with this Offering.

The securities described above were offered pursuant to a registration statement on Form F-1, as amended (File No. 333- 298981) (the “Registration Statement”), which was declared effective by the Securities and Exchange Commission (the “SEC”) on September 24, 2026. The Offering was made only by means of a prospectus which was a part of the Registration Statement. Before you invest, you should read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov. Electronic copies of the final prospectus may be obtained, when available, from Kingswood Capital Partners, LLC  7280 W Palmetto Park Rd. Suite 301, Boca Raton, FL 33433, or by email at lciervo@kingswoodus.com, or by telephone at +1-800-535-6981.

This press release has been prepared for informational purposes only and shall not constitute an offer to sell or the solicitation of an offer to buy any securities, and no sale of these securities may be made in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s Registration Statement and other filings with the SEC, which are available for review at www.sec.gov.

About STAR FASHION CULTURE HOLDINGS LIMITED

STAR FASHION CULTURE HOLDINGS LIMITED (the “Company”) is a content marketing solutions services provider with a mission to offer high-quality diversified services. We offer services focusing on (i) marketing campaign planning and execution; (ii) offline advertising services; and (iii) online precision marketing services. We assist customers in enhancing the effectiveness of their marketing activities and the value of their brand and products through our variety of services offered. The Company first began operations in August 11, 2015 through its operating subsidiary, Xiamen Star Fashion Culture Media Co., Ltd.

For enquiry, please contact:

STAR FASHION CULTURE HOLDINGS LIMITED

12F, No.611, Sishui Road

Huli District,

Xiamen

People’s Republic of China

Tel: +86 13063138565

• DEGEVMA™ is now FDA-approved across all indications of the reference product, Xgeva^® (denosumab), to help prevent bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.
• FDA approval of DEGEVMA marks another milestone in Teva’s Pivot to Growth strategy, demonstrating our ability to bring high-quality, more affordable treatment options to patients across complex therapeutic categories.
• DEGEVMA is Teva’s second FDA-approved biosimilar in 2026 and, together with PONLIMSI™ (denosumab-adet), establishes Teva’s comprehensive denosumab biosimilar portfolio across the indications of the reference products Xgeva^® and Prolia^® (denosumab).

TEL AVIV, Israel, and PARSIPPANY, N.J., Sept. 28, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has approved DEGEVMA™ (denosumab-adet) as a biosimilar to Xgeva^® (denosumab). DEGEVMA is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

The FDA approval of DEGEVMA, together with PONLIMSI (denosumab-adet), which was approved by the FDA in March 2026, establishes a comprehensive U.S. denosumab biosimilar portfolio spanning the indications of both Xgeva^® and Prolia^® (denosumab), respectively. Now, healthcare professionals and patients are able to gain expanded access to biologic treatment options in oncology-related bone disease and osteoporosis care.

“Our R&D mission is grounded in a clear commitment: translating complex biologic science into high-quality treatment options that address patient needs,” said Rob Cook, Head of Global Technical Development & Generics R&D at Teva. “The approval of DEGEVMA reflects the scientific, clinical and regulatory expertise behind our in-house biosimilars capabilities and our continued focus on expanding access to important biologic medicines.”

Biologics like denosumab represent a significant portion of healthcare expenditures, particularly in oncology. The introduction of biosimilars is critical to driving down systemic healthcare costs while broadening patient access to complex, life-enhancing medications.

“The last thing a person living with a cancer diagnosis or their families should have to worry about is access to their medicine,” said Thomas Rainey, Senior Vice President, U.S. Biosimilars at Teva. “The approval of DEGEVMA is a powerful example of Teva’s Pivot to Growth strategy in action because it represents an important step in expanding treatment options for patients and supporting healthcare systems with a high-quality biosimilar.”

The FDA approval of DEGEVMA was based on a totality of evidence, including analytical and clinical data demonstrating similar efficacy, safety and immunogenicity profile as the reference product, Xgeva^®. DEGEVMA is a human monoclonal antibody that binds to the RANKL protein, an essential regulator of osteoclast formation, function and survival. By inhibiting RANKL, DEGEVMA decreases bone resorption and cancer-induced bone destruction. The comprehensive data package submitted to the FDA demonstrated that DEGEVMA has no clinically meaningful differences from the reference product in terms of safety, purity and potency.

Teva anticipates launching DEGEVMA and PONLIMSI in the U.S. in the coming months, aligning with its broader biosimilar commercialization strategy.

DEGEVMA is currently approved in the European Union (EU). Learn more about Teva’s global biosimilars portfolio and commercialization capabilities at www.tevabiosimilars.com.

Use of Trademarks
Xgeva^® and Prolia^® are registered trademarks of Amgen, Inc.

About DEGEVMA
DEGEVMA (denosumab) is indicated for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone and for the treatment of hypercalcemia of malignancy.

The active substance, denosumab, is a human monoclonal IgG2 antibody that targets the protein RANKL, essential for the formation, function, and survival of osteoclasts—the cells responsible for bone resorption. By binding to RANKL with high affinity and specificity, denosumab prevents the interaction between RANKL and RANK, leading to a decrease in bone resorption in cortical and trabecular bone.

DEGEVMA will be available as a 120mg/1.7mL solution for injection in a vial.

DEGEVMA is a biosimilar medicinal product, similar to the reference product Xgeva^® (denosumab), which was approved in the EU on November 18, 2025.

Comprehensive analytical, preclinical, and clinical data demonstrate that DEGEVMA has comparable quality, safety and efficacy to the reference product.

INDICATIONS
DEGEVMA is indicated for the prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors.

DEGEVMA is indicated for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity.

DEGEVMA is indicated for the treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy.

IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Pre-existing hypocalcemia must be corrected prior to initiating therapy with DEGEVMA.

DEGEVMA is contraindicated in patients with known clinically significant hypersensitivity to DEGEVMA or denosumab products.

WARNINGS AND PRECAUTIONS
Drug Products with Same Active Ingredient
Patients receiving DEGEVMA should not receive other denosumab products.

Hypersensitivity
Clinically significant hypersensitivity including anaphylaxis has been reported with use of DEGEVMA. Reactions may include hypotension, dyspnea, upper airway edema, lip swelling, rash, pruritus, and urticaria. If an anaphylactic or other clinically significant allergic reaction occurs, initiate appropriate therapy and discontinue DEGEVMA therapy permanently.

Hypocalcemia
DEGEVMA can cause severe symptomatic hypocalcemia, and fatal cases have been reported. Correct pre-existing hypocalcemia prior to DEGEVMA treatment. Monitor calcium levels, throughout DEGEVMA therapy, especially in the first weeks of initiating therapy, and administer calcium, magnesium, and vitamin D as necessary. Concomitant use of calcimimetics and other drugs that can lower calcium levels may worsen hypocalcemia risk and serum calcium should be closely monitored. Advise patients to contact a healthcare provider for symptoms of hypocalcemia. Do not take DEGEVMA if you are allergic to denosumab or any of the ingredients of DEGEVMA.

An increased risk of hypocalcemia has been observed in clinical trials of patients with increasing renal dysfunction, most commonly with severe dysfunction (creatinine clearance less than 30 mL/min and/or on dialysis), and with inadequate/no calcium supplementation. Monitor calcium levels and calcium and vitamin D intake.

Osteonecrosis of the Jaw (ONJ)
Osteonecrosis of the jaw (ONJ) has been reported in patients receiving DEGEVMA, manifesting as jaw pain, osteomyelitis, osteitis, bone erosion, tooth or periodontal infection, toothache, gingival ulceration, or gingival erosion. Persistent pain or slow healing of the mouth or jaw after dental surgery may also be manifestations of ONJ. In clinical trials in patients with cancer, the incidence of ONJ was higher with longer duration of exposure. Patients with a history of tooth extraction, poor oral hygiene, or use of a dental appliance are at a higher risk of developing ONJ. Other risk factors for the development of ONJ include immunosuppressive therapy, treatment with angiogenesis inhibitors, systemic corticosteroids, diabetes, and gingival infections.

Perform an oral examination and appropriate preventive dentistry prior to the initiation of DEGEVMA and periodically during DEGEVMA therapy. Advise patients regarding oral hygiene practices. Avoid invasive dental procedures during treatment with DEGEVMA. Consider temporary discontinuation of DEGEVMA therapy if an invasive dental procedure must be performed.

Patients who are suspected of having or who develop ONJ while on DEGEVMA should receive care by a dentist or an oral surgeon. In these patients, extensive dental surgery to treat ONJ may exacerbate the condition.

Atypical Subtrochanteric and Diaphyseal Femoral Fracture
Atypical femoral fracture has been reported with DEGEVMA. These fractures can occur anywhere in the femoral shaft from just below the lesser trochanter to above the supracondylar flare and are transverse or short oblique in orientation without evidence of comminution.

Atypical femoral fractures most commonly occur with minimal or no trauma to the affected area. They may be bilateral, and many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs. A number of reports note that patients were also receiving treatment with glucocorticoids (e.g., prednisone) at the time of fracture.

During DEGEVMA treatment, patients should be advised to report new or unusual thigh, hip, or groin pain. Any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture. Patients presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb. Interruption of DEGEVMA therapy should be considered, pending a risk/benefit assessment, on an individual basis.

Hypercalcemia Following Treatment Discontinuation in Patients with Giant Cell Tumor of Bone and in Patients with Growing Skeletons
Clinically significant hypercalcemia requiring hospitalization and complicated by acute renal injury has been reported in DEGEVMA-treated patients with giant cell tumor of bone and patients with growing skeletons. Within the first year after treatment discontinuation, monitor patients for signs and symptoms of hypercalcemia and treat appropriately.

Multiple Vertebral Fractures (MVF) Following Treatment Discontinuation
Multiple vertebral fractures (MVF) have been reported following discontinuation of treatment with denosumab products. Patients at higher risk for MVF include those with risk factors for or a history of osteoporosis or prior fractures.

When DEGEVMA treatment is discontinued, evaluate the individual patient’s risk for vertebral fractures.

Embryo-Fetal Toxicity
Based on data from animal studies and its mechanism of action, denosumab products can cause fetal harm when administered to a pregnant woman.

Advise pregnant women and females of reproductive potential that exposure to DEGEVMA during pregnancy or within 5 months prior to conception can result in fetal harm.

ADVERSE REACTIONS
The most common adverse reactions in patients with bone metastases from solid tumors taking DEGEVMA were fatigue/asthenia, hypophosphatemia, and nausea. The most common serious side effect was dyspnea.

In patients with multiple myeloma, the most common adverse reactions were diarrhea, nausea, anemia, back pain, thrombocytopenia, peripheral edema, hypocalcemia, upper respiratory tract infection, rash, and headache. The most common serious side effect of DEGEVMA was osteonecrosis of the jaw.

To report SUSPECTED ADVERSE REACTIONS, contact Teva Pharmaceuticals at 1-888-483-8279 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see the full Prescribing Information for DEGEVMA.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Teva Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully commercialize DEGEVMA (denosumab-adet) a Biosimilar to Xgeva^® (denosumab) for the prevention of bone complications in adults with advanced cancer that has spread to the bone, for the treatment of adults and skeletally mature adolescents with giant cell tumor of bone, and for the treatment of hypercalcemia of malignancy, and PONLIMSI (denosumab-adet); our ability to successfully compete in the marketplace including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to execute on our organizational transformation and to achieve expected cost savings; and other factors discussed in this press release, in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the section captioned “Risk Factors” and “Forward-looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

Teva Media Inquiries:	TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:	TevaIR@Tevapharm.com

ALEXANDRIA, Va., Sept. 28, 2026 (GLOBE NEWSWIRE) — Burke & Herbert Financial Services Corp. (the “Company”) (Nasdaq: BHRB), the holding company for Burke & Herbert Bank & Trust Company (the “Bank”), today announced the pricing of its public offering of $100.0 million aggregate principal amount of its 7.00% Fixed-to-Floating Rate Subordinated Notes due 2036 (the “Notes”). The price to the public for the Notes is 100% of the principal amount of the Notes. The Notes will mature on October 1, 2036. Interest on the Notes initially will accrue at a rate equal to 7.00% per annum from and including September 30, 2026 to, but excluding, October 1, 2031, payable semiannually in arrears. From and including October 1, 2031 to, but excluding, October 1, 2036, or the earlier redemption date, interest will accrue at a floating rate per annum equal to the Three-Month Term SOFR, or other applicable Benchmark rate (as defined in the Notes), plus a spread of 222 basis points, payable quarterly in arrears. The Notes are intended to qualify as Tier 2 capital for regulatory purposes.

The offering is expected to close on September 30, 2026, subject to the satisfaction of customary closing conditions.

Beginning with the interest payment date of October 1, 2031 and on any interest payment date thereafter, the Company may, at its option, redeem the Notes, in whole or in part, at a redemption price equal to 100.00% of par, plus accrued and unpaid interest to but excluding the date of redemption. The Company may also redeem the Notes, in whole but not in part, at any time, including prior to October 1, 2031, upon the occurrence of certain specified events.

Keefe, Bruyette & Woods, A Stifel Company, acted as the sole book-running manager for the Notes offering.

The Company intends to use the net proceeds from this offering, plus cash on hand: (i) to repay $4.5 million aggregate principal amount of its outstanding 6.875% Subordinated Note, which matures on April 1, 2028 (the “2028 Note”); $18.1 million aggregate principal amount of its outstanding 6.00% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the Three-Month Term SOFR plus 590 basis points and mature on July 1, 2030 (the “July 2030 Notes”); and $20.0 million aggregate principal amount of its outstanding 5.00% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the Three-Month Term SOFR plus 475 basis points and mature on October 1, 2030 plus, in each case, accrued and unpaid interest; (ii) to potentially repay all or part of its outstanding $75.0 million aggregate principal amount of 3.25% Fixed-to-Floating Rate Subordinated Notes, which currently bear interest at the fixed rate of 3.25% per year and mature on December 1, 2031, plus accrued and unpaid interest; (iii) to potentially redeem all or part of its outstanding $15.0 million aggregate liquidation preference of 2021 Preferred Stock, which has dividends payable in arrears, when, as and if authorized and declared by the board of directors of the Company out of legally available funds, on a non-cumulative basis at the $10,000 per share purchase price, at an annual rate equal to 6.00%; and (iv) for general corporate purposes, including providing capital to the Bank to support its growth. A conditional notice of redemption was delivered to the holders of the Company’s July 2030 Notes with respect to the redemption of all of the outstanding principal amount of such notes. The redemption of the Company’s July 2030 Notes is contingent on this offering of the Notes and the amount of proceeds resulting from this offering. A notice of prepayment was delivered to the holder of the 2028 Note but is not contingent on this offering of the Notes.

The offering of the Notes is being made by means of a prospectus supplement and an accompanying base prospectus. The Company previously filed with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement (File No. 333-283261) and has filed a preliminary prospectus supplement to the base prospectus contained in the registration statement for the Notes to which this communication relates. The Company will file a final prospectus supplement relating to the Notes. Prospective investors should read the base prospectus contained in the registration statement, the preliminary prospectus supplement, the final prospectus supplement and the other documents the Company has filed or will file with the SEC for more complete information about the Company and the Notes offering.

Copies of these documents, when available, can be obtained for free by visiting EDGAR on the SEC’s website at www.sec.gov, or by contacting Keefe, Bruyette & Woods, Inc., toll-free at (800) 966-1559 or by emailing USCapitalMarkets@kbw.com.

No Offer or Sale

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Notes, nor shall there be any sale of the Notes in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offering of the Notes is being made only by means of a written prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended. The Notes being offered have not been approved or disapproved by any regulatory authority, nor has any such authority passed upon the accuracy or adequacy of the registration statement, the base prospectus contained in the registration statement, the preliminary prospectus supplement or the final prospectus supplement relating thereto.

About Burke & Herbert

Burke & Herbert Financial Services Corp. is the financial holding company for Burke & Herbert Bank & Trust Company. Burke & Herbert Bank & Trust Company is the oldest continuously operating bank under its original name headquartered in the greater Washington, D.C. metropolitan area. With over 100 branches across Delaware, Kentucky, Maryland, Pennsylvania, Virginia, and West Virginia, Burke & Herbert Bank & Trust Company offers a full range of business and personal financial solutions designed to meet customers’ banking, borrowing, and investment needs. Learn more at investor.burkeandherbertbank.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including with respect to (or based on) the beliefs, goals, intentions, and expectations of Burke & Herbert. Forward–looking statements are typically identified by such words as “believe,” “expect,” “anticipate,” “intend,” “outlook,” “estimate,” “forecast,” “project,” “will,” “should,” and other similar words and expressions, and are subject to numerous assumptions, risks, and uncertainties, which change over time. Additionally, forward-looking statements speak only as of the date they are made; Burke & Herbert does not assume any duty, and does not undertake, to update such forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future events, or otherwise. Furthermore, because forward-looking statements are subject to assumptions and uncertainties, actual results or future events could differ, possibly materially, from those indicated in or implied by such forward-looking statements as a result of a variety of factors, many of which are beyond the control of Burke & Herbert. Such statements are based upon the current beliefs and expectations of the management of Burke & Herbert and are subject to significant risks and uncertainties outside of its control. Caution should be exercised against placing undue reliance on forward-looking statements.

Potential risks and uncertainties include, but are not limited to, the Company’s ability to complete the offering and to deploy the net proceeds of the offering as the Company currently expects. The Company cautions readers that the foregoing list of factors is not exclusive, is not necessarily in order of importance and readers should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and the Company does not intend to and, except as required by applicable law, disclaims any obligation to update or revise any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events, unless required to do so under applicable securities laws.

Media Contact: Investor Relations 703-666-3555 bhfsir@burkeandherbertbank.com

Company highlights a significant institutional milestone, advancing its intended regulated-exchange uplist through institutional custody, deployed SVLT infrastructure, proprietary nanotechnology, international real-world asset initiatives and its ongoing IFRS audit programme

JOHANNESBURG, South Africa, Sept. 28, 2026 (GLOBE NEWSWIRE) — ProText Mobility, Inc. (OTC: TXTM) (“TXTM”) today issues its Inter-Quarter Shareholder Update, as referenced in the Company’s Q2 filings, highlighting significant developments in its institutional digital-asset infrastructure strategy, international relationships and expanding real-world asset (RWA) initiatives.

At the centre of this update is a development that the Company has been working toward:

ABSA BANK HAS CONFIRMED THE COMPANY’S CHAIRMAN’S PARTICIPATION AS ITS FIRST PILOT CLIENT IN ITS DIGITAL-ASSET CUSTODY ONBOARDING PROCESS.

This represents a significant milestone in TXTM’s strategy of connecting real-world assets, proprietary technology, digital tokenisation and regulated institutional financial infrastructure.

For the Company, institutional custody represents a critical component of its broader roadmap. The objective has never been simply to create digital tokens.
It has been to develop the technological, commercial and institutional infrastructure necessary to support a scalable ecosystem connecting real-world economic activity with the emerging digital financial economy.

Importantly, these developments form part of TXTM’s broader corporate strategy as the Company advances its intended UPLIST TO A REGULATED EXCHANGE.

The Company’s institutional infrastructure initiatives, ongoing IFRS audit programme, international asset development and strategic relationships are designed to strengthen its institutional readiness and support the next stage of its capital-markets evolution.

The confirmation of ABSA’s inaugural pilot relationship represents an important advancement toward that objective.

THE INSTITUTIONAL CONNECTION WE HAVE BEEN WORKING TOWARD IS NOW ESTABLISHED AT THE PILOT LEVEL.

The Company is advancing from infrastructure development toward institutional implementation, with its intended uplist remaining a central corporate objective.

1.  ABSA × RIPPLE × TXTM: A SIGNIFICANT INSTITUTIONAL MILESTONE

ABSA has directly confirmed the Company’s Chairman’s participation as its first pilot client in its digital-asset custody onboarding process.

In correspondence to the Chairman, ABSA stated:

“Your participation is helping us test and refine not only the operational aspects of the service, but also the governance, risk and compliance requirements that a regulated bank must satisfy when supporting tokenised assets.”

This confirmation is significant.

ABSA is developing the operational, governance, risk and compliance framework required to support tokenised assets within a regulated banking environment.

The Company’s inaugural pilot participation places it within that process.

The Company has already developed and deployed its SVLT tokenisation infrastructure while pursuing the institutional relationships required to support its longer-term strategy.

The ABSA pilot provides an opportunity to bring these components together.

Separately, in October 2025, Ripple announced its partnership with ABSA to provide institutional digital-asset custody technology in South Africa.

OFFICIAL ANNOUNCEMENT — ABSA AND RIPPLE:

https://ripple.com/ripple-press/ripple-expands-global-custody-footprint-into-africa-with-absa-bank/

The emerging architecture can be illustrated as follows:

RIPPLE

ABSA’s publicly announced custody technology provider.

↓

ABSA

Institutional digital-asset custody infrastructure.

↓

TXTM / SVLT

Confirmed inaugural custody pilot participation.

↓

REAL-WORLD ASSETS

Existing tokenised assets and expanding asset pipeline.

This is a conceptual architecture and does not imply a direct commercial agreement between TXTM and Ripple.

The Company distinguishes its confirmed pilot participation with ABSA from any separate commercial relationship with Ripple.

Nevertheless, the strategic significance of this development is substantial. TXTM has been building its real-world asset infrastructure.
ABSA is developing institutional custody infrastructure.

The Company’s participation in ABSA’s inaugural pilot creates an opportunity to advance the connection between these two environments.

As TXTM progresses toward its intended uplist, this institutional relationship represents an important component of its broader effort to strengthen governance, operational infrastructure and institutional readiness.

THIS IS AN IMPORTANT ENABLING MILESTONE FOR THE ROADMAP.

2.  SVLT: CONNECTING TOKENISED REAL-WORLD ASSETS WITH INSTITUTIONAL INFRASTRUCTURE

SVLT represents an important component of the Company’s developing digital-asset infrastructure.

Deployed using an ERC-3643 permissioned token architecture, SVLT incorporates identity, compliance and administrative functionality intended to support institutional requirements.

Importantly, the Company’s agricultural seed initiative has already been tokenised.

The Company’s strategy is to connect qualifying real-world assets with a framework incorporating independent verification, tokenisation, governance and institutional custody.

TXTM’S RWA INFRASTRUCTURE

REAL-WORLD ASSETS

↓

INDEPENDENT VALUATION AND VERIFICATION

↓

SVLT TOKENISATION

↓

REGULATED INSTITUTIONAL CUSTODY

↓

COLLATERAL AND FINANCIAL UTILITY

The ABSA pilot represents progress toward the institutional custody component of this architecture. The Company is continuing the applicable operational, cybersecurity and onboarding processes.
The established SVLT infrastructure provides a foundation for expanding the model to other qualifying asset classes, including the Company’s pharmaceutical-related initiatives.

Future custody services and specific financing arrangements remain subject to their applicable commercial and regulatory requirements.

Importantly, the strategy does not begin or end with a single token.

SVLT is intended to support a broader ecosystem involving multiple qualifying asset classes, projects and jurisdictions.

3.  PROPRIETARY NANOTECHNOLOGY: DEVELOPING UNDERLYING ECONOMIC VALUE

A fundamental distinction in TXTM’s strategy is the integration of its proprietary nanotechnology and associated technological capabilities with its developing RWA infrastructure.

The Company is pursuing opportunities to apply these capabilities across qualifying commercial sectors, including agriculture and environmental applications.

The strategic objective is to develop measurable economic value that can subsequently qualify for digital representation and institutional financial applications.

THE COMPANY’S INTENDED MODEL:

PROPRIETARY TECHNOLOGY

↓

ECONOMIC ACTIVITY

↓

MEASURABLE ASSETS

↓

INDEPENDENT VERIFICATION

↓

TOKENISATION

↓

INSTITUTIONAL CONNECTIVITY

This creates the potential for an expanding asset pipeline.

As additional technologies, projects and commercial applications demonstrate independently supportable economic value, the Company intends to evaluate their eligibility for inclusion within its broader RWA ecosystem.

The Company recognises that technological potential does not automatically establish recognised balance-sheet value or tokenisation eligibility.

Commercialisation, appropriate accounting treatment, legal rights, independent valuation and verification remain essential.

The integration of proprietary technology with institutional digital-asset infrastructure represents an important element of TXTM’s long-term strategy.

4.  BRICS 2026, AfCFTA, CARICOM AND GRULAC: BUILDING INTERNATIONAL RELATIONSHIPS

The Company’s Chairman recently returned from India following his participation in BRICS 2026-related engagements.

These activities form part of the Company’s continuing efforts to establish international relationships and identify opportunities connecting real-world economic development with institutional financial infrastructure.

During his visit, the Chairman also met with His Excellency Jason Hall, Jamaica’s High Commissioner to India.

These engagements complement the Company’s broader relationship-building activities across Africa, BRICS economies, the Caribbean and Latin America.

The Company recognises the importance of the African Continental Free Trade Area (AfCFTA), the Caribbean Community (CARICOM) and the United Nations Group of Latin American and Caribbean Countries (GRULAC) within the wider economic and diplomatic landscape.

Together, these regions represent substantial opportunities involving agriculture, energy, natural resources, environmental infrastructure, technology and international trade.

The Company’s objective is to develop commercially viable relationships and identify qualifying projects across these markets.

These international engagements do not constitute commercial agreements with the regional organisations themselves.

Rather, they provide important context for the Company’s developing international strategy.

DIFFERENT MARKETS. DIFFERENT RESOURCES. ONE INCREASINGLY CONNECTED ECONOMIC LANDSCAPE.

5.  VENEZUELA: A CIRCULAR AGRICULTURAL AND ENERGY INFRASTRUCTURE OPPORTUNITY

The Company is advancing its Venezuela initiative, which involves a signed government pilot.

The proposed initiative introduces a circular agricultural infrastructure model connecting food production with potential renewable energy, resource recovery and environmental value creation.

The proposed process incorporates rice production, agricultural residue recovery, suitable biomass processing, biogas generation, renewable power and heat, and potential fertilizer and water recovery.

Subject to engineering and commercial feasibility, renewable electricity may also support future green-hydrogen production.

VENEZUELA: PROPOSED INTEGRATED VALUE CHAIN

01 — RICE PRODUCTION

02 — AGRICULTURAL RESIDUES

03 — BIOGAS GENERATION

04 — RENEWABLE POWER AND HEAT

05 — FERTILIZER AND RESOURCE RECOVERY

06 — POTENTIAL GREEN HYDROGEN

07 — POTENTIAL VERIFIED ENVIRONMENTAL ATTRIBUTES

Environmental attributes remain subject to eligible methodologies, independent verification and measurement, reporting and verification requirements.

The broader objective is to demonstrate how integrated agricultural infrastructure can create multiple measurable economic value streams.

Engineering feasibility, regulatory approvals, independent verification and project financing will determine which components can be commercially implemented.

Qualifying economic assets and contractual rights arising from such projects may subsequently be evaluated for inclusion within the Company’s RWA strategy.

6.  BRIGHTLY VENTURES AND B TERRA CORP: EXPANDING THE REAL-WORLD ASSET PIPELINE

The Company’s strategic relationships with Brightly Ventures and B Terra Corp represent additional elements of its developing ecosystem.

BRIGHTLY VENTURES

The Brightly relationship introduces opportunities involving environmental measurement, data infrastructure, verification and the development of qualifying environmental assets.

Measurement and independent verification are fundamental to establishing credible environmental economic value.

The Company intends to evaluate how these capabilities may complement its broader RWA and institutional infrastructure strategy.

THE INTERNATIONAL CARBON-MARKET CONNECTION

In April 2026, Xpansiv announced its planned offering of Brightly’s food-waste methane-reduction carbon credits through its CBL exchange.

The announcement identified an initial offering of approximately 250,000 ex-ante credits, with potential expansion to 500,000.

OFFICIAL ANNOUNCEMENT — BRIGHTLY AND XPANSIV:

https://www.xpansiv.com/news/xpansiv-to-launch-first-of-their-kind-food-waste-carbon-credits-from-brightly-on-cbl-exchange

This development is particularly relevant to the Company’s environmental and real-world asset strategy.

Separately, in October 2023, the Johannesburg Stock Exchange announced its collaboration with Xpansiv to establish an African voluntary carbon marketplace through JSE Ventures.

The marketplace provides access to international infrastructure for transactions involving qualifying carbon credits and renewable energy certificates.

OFFICIAL ANNOUNCEMENT — JSE AND XPANSIV:

https://www.jse.co.za/news/news/jse-collaborates-xpansiv-launch-voluntary-carbon-market-advance-south-africas-carbon

These independently announced developments demonstrate how environmental projects, carbon-market infrastructure and international financial markets are becoming increasingly connected.

They also provide relevant market context for TXTM’s broader RWA strategy and international ambitions.

Brightly’s announced relationship with Xpansiv and the JSE’s separate collaboration with Xpansiv do not constitute direct agreements between TXTM and those market operators.

Nevertheless, the developments illustrate a broader opportunity to connect independently verified environmental assets with established international market infrastructure.

B TERRA CORP

The Company’s strategic letter of intent with B Terra Corp introduces another potential component of its developing real-world asset pipeline.

Both relationships remain subject to their respective commercial milestones and definitive arrangements where applicable.

The Company’s objective is to develop a diversified ecosystem involving independently supportable assets, multiple commercial applications and appropriate institutional infrastructure.

7.  NATIVE NATIONS, INDIGENOUS ECONOMIES AND JURISDICTIONAL SOVEREIGNTY

South Africa’s Heritage Day, celebrated on September 24, provides an appropriate occasion to recognise the relationship between heritage, economic development and the stewardship of real-world resources.

The ancient Khoisan peoples of Southern Africa form an important part of this heritage.

The Company’s engagement with Native Nations introduces another dimension to its international strategy.

TXTM is exploring how modern digital infrastructure may interact with indigenous economic development while respecting the distinct legal, governmental and sovereign frameworks of participating communities.

Potential applications may include agriculture, natural resources, renewable energy, environmental stewardship, infrastructure, intellectual property and community enterprises.

Every jurisdiction and participating Native Nation has its own legal and governmental framework.

Any future initiative must respect applicable indigenous rights, land rights, governmental authority, legal requirements and community decision-making processes.

TECHNOLOGY MUST SERVE PEOPLE AND THEIR JURISDICTIONS — NOT REPLACE THEM.

This principle remains central to the Company’s approach.

8.  AN INCREASINGLY CONNECTED GLOBAL RWA ARCHITECTURE

The Company’s individual initiatives are designed to contribute to a broader strategic architecture.

TXTM’S DEVELOPING ECOSYSTEM

PROPRIETARY TECHNOLOGY

Nanotechnology and related opportunities for economic development.

REAL-WORLD ASSET DEVELOPMENT

Venezuela, Brightly, B Terra and other potential qualifying international projects.

SVLT INFRASTRUCTURE

Permissioned tokenisation, identity, compliance and asset administration.

INSTITUTIONAL CUSTODY

ABSA’s confirmed inaugural pilot participation and associated onboarding processes.

INTERNATIONAL CONNECTIVITY

Developing relationships across Africa, BRICS economies, the Caribbean, Latin America and Native Nations.

These initiatives involve different assets, jurisdictions, commercial arrangements and stages of development.

The Company’s objective is to connect qualifying opportunities through a common framework incorporating technology, governance, verification, compliance and institutional infrastructure.

The ABSA pilot represents an important milestone within that architecture.

Together, these initiatives are intended to strengthen the Company’s institutional foundation as it advances its proposed regulated-exchange uplist.

9.  THE NEXT PHASE: INSTITUTIONAL IMPLEMENTATION AND TXTM’S UPLIST STRATEGY

With the inaugural ABSA pilot relationship confirmed, the Company is advancing the next phase of its roadmap.

Its priorities include:

• Progressing ABSA’s applicable custody onboarding, cybersecurity and operational requirements.
• Advancing SVLT’s institutional governance, compliance and asset administration infrastructure.
• Continuing the Company’s IFRS audit and financial reporting programme.
• Developing qualifying assets and commercial opportunities through its existing strategic relationships.
• Advancing the Company’s intended regulated-exchange uplist strategy and evaluating appropriate institutional financing pathways.

STRENGTHENING THE FINANCIAL FOUNDATION FOR UPLISTING

TXTM’s voluntary financial reporting programme represents another important component of its institutional-readiness strategy.

The Company has completed its 2022 and 2023 audits and is advancing its 2024 and 2025 IFRS audit programme.

Its existing Canadian engagement forms part of the next stage of its international financial reporting preparations.

This programme extends beyond the general independent-audit requirements applicable to qualifying OTCID issuers under the OTC Markets Alternative Reporting Standard.

In addition to improving international comparability, the programme provides an opportunity to establish the appropriate IFRS treatment of qualifying agricultural, pharmaceutical and other assets, including applicable foreign-currency translation effects.

The Company recognises that IFRS asset measurement and currency translation are distinct accounting considerations.

Their actual effects on reported assets, profit and shareholders’ equity will depend on the applicable accounting requirements and completed independent audits.

These initiatives are intended to support institutional due diligence, the Company’s planned regulated-exchange uplist and the continued development of long-term franchise value.

ADVANCING THE COMPANY’S REGULATED-EXCHANGE UPLIST

The Company’s intended uplist remains a central objective of its corporate strategy.

TXTM’s roadmap is designed to support its progression toward regulated-exchange listings and expanded participation in institutional capital markets.

The Company continues developing the financial reporting, corporate governance, institutional infrastructure and strategic relationships necessary to support that objective.

Its ongoing IFRS audit programme, proprietary technologies, SVLT infrastructure, developing real-world asset pipeline and institutional relationships represent complementary components of this strategy.

The objective is to establish a stronger institutional foundation, expand access to regulated capital markets and create opportunities for broader investor participation.

The Company will continue evaluating suitable exchange pathways, transaction structures and applicable regulatory requirements.

THE JSE: AN ADDITIONAL INTERNATIONAL CAPITAL-MARKETS OPPORTUNITY

In October 2022, the New York Stock Exchange and Johannesburg Stock Exchange announced an agreement concerning collaboration on dual listings.

The agreement also included exploration of opportunities involving ESG, exchange-traded funds and digital assets.

NYSE–JSE COLLABORATION:

https://www.businesswire.com/news/home/20221010005789/en/The-New-York-Stock-Exchange-and-The-Johannesburg-Stock-Exchange-Announce-Collaboration-on-Dual-Listings

This is particularly relevant to TXTM’s broader international strategy and its developing environmental and real-world asset initiatives.

In addition, the JSE’s revised listing requirements provide an expanded fast-track secondary-listing framework, including a 12-month minimum primary-listing period on an approved exchange.

OFFICIAL JSE FAST-TRACK SECONDARY-LISTING ANNOUNCEMENT:

https://www.jse.co.za/news/news/fsca-greenlights-jse-simplification-project

Following a successful qualifying primary uplist, TXTM intends to evaluate a potential secondary listing on the JSE.

Any such listing would remain subject to the Company’s primary listing venue, applicable eligibility requirements, regulatory approvals and completion of the necessary processes.

These exchange-level developments are not agreements with TXTM.

They nevertheless provide an established international regulatory and market framework relevant to the Company’s longer-term strategy.

THE ROADMAP TO UPLIST

INSTITUTIONAL READINESS

↓

STRONGER GOVERNANCE AND FINANCIAL REPORTING

↓

VERIFIED REAL-WORLD ECONOMIC VALUE

↓

REGULATED-EXCHANGE UPLIST

↓

LONG-TERM SHAREHOLDER VALUE

These are strategic objectives, not completed milestones or assured outcomes.

THE OBJECTIVE: INSTITUTIONAL READINESS, REGULATED MARKET ACCESS AND LONG-TERM SHAREHOLDER VALUE.

Institutional custody represents a key enabling component of the Company’s strategy.

The Company will continue evaluating institutional financing opportunities and intends to provide further shareholder updates as material milestones are achieved.

Any proposed uplist remains subject to applicable exchange listing standards, financial and governance requirements, regulatory approvals and completion of the relevant processes.

FROM INFRASTRUCTURE DEVELOPMENT TO INSTITUTIONAL IMPLEMENTATION. FROM INSTITUTIONAL IMPLEMENTATION TOWARD A REGULATED-EXCHANGE UPLIST. THE ROADMAP IS MOVING.

10.   MESSAGE FROM THE CHAIRMAN

Dr. Ahmed Jamaloodeen, Chairman of ProText Mobility, Inc., stated:

“Our shareholders have remained with us as we have pursued a strategy extending beyond any single technology, asset class, financial institution or jurisdiction.

“We recognised early that meaningful real-world asset tokenisation would require more than blockchain technology.

“It would require real assets, independently supportable valuations, governance, regulatory compliance, institutional relationships and appropriate custody infrastructure.

“ABSA’s confirmation of our inaugural pilot participation represents an important milestone in that journey.

“One of the key institutional relationships we have been working toward is now established at the pilot level.

“This enables us to advance the next phase of our strategy, connecting proprietary technology, real-world economic development and institutional financial infrastructure.

“Our intended uplist remains a central objective of our corporate strategy.

“Our IFRS audit programme, proprietary technology, international initiatives, SVLT infrastructure and ABSA custody pilot are components of this broader strategy.

“We are voluntarily investing in international financial reporting standards and developing the institutional foundations necessary to support our future.

“Our objective is to establish an institutional foundation capable of supporting our intended uplist and creating sustainable long-term value for our shareholders.

“The roadmap is not simply about tokenisation. It is about strengthening our institutional infrastructure, developing independently supportable economic value and advancing the Company’s capital-markets strategy.

“Our focus remains on governance, compliance, verification, custody, jurisdiction, scalability and execution.

“We thank our shareholders for their continued patience, confidence and support.

“THE ROADMAP IS MOVING.”

11.   HERITAGE, RESONANCE AND OUR SHARED FUTURE

The Company’s international vision recognises that meaningful economic development must respect the people, communities, cultures and jurisdictions that create and sustain real-world value.

As South Africa celebrates its heritage, TXTM recognises the importance of building economic relationships across cultures and borders.

The Company’s guiding philosophy remains: 432 Hz

RESONANCE → ALIGNMENT → EXECUTION

SIMUNYE

WE ARE ONE.

Different countries. Different cultures. Different jurisdictions. Different assets. Different technologies.

ONE INCREASINGLY CONNECTED VISION.

From heritage to real-world value.

From real-world value to institutional infrastructure.

From institutional infrastructure toward a regulated-exchange uplist. From institutional infrastructure to the digital economy.

THE ROADMAP IS MOVING.

ABOUT PROTEXT MOBILITY, INC.

ProText Mobility, Inc. is pursuing a strategy involving proprietary technology, real-world assets, digital tokenisation and institutional financial infrastructure.

The Company’s roadmap incorporates international relationship development and opportunities to connect qualifying economic assets with compliant digital financial infrastructure.

The Company is advancing an intended regulated-exchange uplist strategy, supported by its ongoing financial reporting programme, institutional infrastructure development and broader real-world asset initiatives.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, including statements concerning the Company’s business strategy, proposed projects, tokenisation infrastructure, commercial relationships, potential financing arrangements, regulatory processes, intended uplist and anticipated developments.

These statements involve risks and uncertainties, and actual results may differ materially from those expressed or implied.

Pilot participation does not guarantee commercial custody services, institutional financing, asset eligibility, liquidity, exchange-listing approval or future revenue.

Proposed transactions and initiatives may require additional agreements, independent verification, regulatory approvals and financing.

The Company’s intended uplist is subject to applicable exchange-listing standards, financial and corporate governance requirements, regulatory processes and other relevant conditions.

The possibility of a subsequent JSE listing would introduce further eligibility requirements and approvals.

No assurance can be given that a proposed uplist will be completed or that any particular exchange will approve the Company’s securities for listing.

The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

INVESTOR RELATIONS & MEDIA CONTACT

Mr. Dylon Du Plooy
Chief Executive Officer Email: dylon@rsammd.co.za
X: https://x.com/MrDylonDuPlooy
Executive profile: https://protxtm.com/mr-d-du-plooy-ceo/

Dr. Ahmed Jamaloodeen (Dr. J)
President & Chairman Email: exportintl@aol.com
X: https://x.com/Dr_Jamaloodeen
Executive profile: https://protxtm.com/dr-a-jamaloodeen-md-chairman/

Company Website: https://protxtm.com/
Investor Relations: https://protxtm.com/investor-relations/

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/85847555-2fbd-44b0-894b-325fe40c75ce

CINCINNATI, Sept. 28, 2026 (GLOBE NEWSWIRE) — The E.W. Scripps Company (NASDAQ: SSP) has promoted veteran news leader Sean McGarvy to head of news, effective Oct. 5.   

McGarvy will lead news and content strategy and oversee news standards for Scripps News Group, bringing Scripps’ local newsrooms, digital operations and Scripps News, the company’s national streaming news network, closer together under a unified, consumer-focused strategy. In this role, he will drive efforts to extend the reach and impact of Scripps’ journalism across broadcast, streaming and digital platforms as the company continues transforming how it delivers trusted journalism and builds stronger community connections.  

McGarvy will report to Dean Littleton, who was promoted to president of media in July. 

“Scripps’ transformation is about evolving our organization to serve audiences and communities in new ways,” Littleton said. “Our journalism is central to that work, and Sean brings the news judgment, operational discipline and audience focus needed to help align our local newsrooms, digital operations and Scripps News around the needs of American news consumers. His leadership will help us move trusted journalism faster across platforms while strengthening the connection between our reporting and the communities we serve.”   

Most recently, McGarvy served as Scripps’ senior director of digital news operations, leading strategy and audience growth across Scripps News Group’s digital platforms, including YouTube and Meta. He has helped expand the reach and impact of the company’s journalism through audience-driven news strategies and a coordinated approach to digital publishing and streaming news. Previously, as senior director of local news strategy, he worked with Scripps’ local TV markets to deepen community connection and strengthen collaboration across Scripps News Group.  

Earlier in his Scripps career, McGarvy was news director at WEWS, Scripps’ ABC affiliate in Cleveland, and assistant news director at KMGH, Scripps’ ABC affiliate in Denver. His career spans almost 30 years in newsrooms across the country, including managing editor and assignment manager roles at local TV stations and Fox News Channel. His work has been recognized with seven Edward R. Murrow Awards and 10 regional Emmy Awards.  

McGarvy holds a Bachelor of Arts degree in broadcast journalism from the University of Missouri in Columbia.  

Media contact: Becca McCarter, The E.W. Scripps Company, (513) 410-2425, rebecca.mccarter@scripps.com

About Scripps
The E.W. Scripps Company (NASDAQ: SSP) is a diversified media company focused on creating connection. As one of the nation’s largest local TV broadcasters, Scripps serves communities with quality, objective local journalism and operates a portfolio of about 60 stations in 40 markets. Scripps reaches households across the U.S. with national news outlet Scripps News and popular entertainment brands ION, Bounce, Grit, ION Mystery, ION Plus and Laff. Scripps is one of the nation’s largest holders of broadcast spectrum. Scripps Sports serves professional and college sports leagues, conferences and teams with local market depth and national broadcast reach of up to 100% of TV households. Founded in 1878, Scripps is the steward of the Scripps National Spelling Bee, and its longtime motto is: “Give light and the people will find their own way.”

Scripps in the news            Scripps press releases

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/5c80b07d-fd26-4481-8163-04d5b3bae28b

• Financial Highlights
  • Cash and cash equivalents totaled €113.8 million as of June 30, 2026; expected to fund the Company beyond the end of 2028
  • €21.1 million in revenues as of June 30, 2026, including €21.0 million in royalties generated under the Ipsen agreement
• Key Highlights
  • PBC: Ipsen doubled its peak annual global sales target for Iqirvo® in PBC to €1 billion, underscoring the value creation potential of GENFIT’s licensing agreement
  • MASH: Medicare coverage secured in August 2026 in the United States for NASHnext®, the Labcorp-commercialized test based on GENFIT’s NIS™ technology; estimated U.S. peak sales of products based on GENFIT’s NIS™ technology could exceed $1.5 billion by 2033 (IQVIA)
  • ACLF: Clinical-stage pipeline re-focused on the planned initiation of two Phase 2 clinical trials, of nangibotide and nitazoxanide, before year-end
  • CCA: Continued advancement of GNS561 in combination therapy, including expansion of the Phase 1b study into additional cohorts following encouraging preliminary data; preparation for a Phase 2 trial expected to commence before year-end

Lille (France), Cambridge (Massachusetts, United States); September 28, 2026 – GENFIT (Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its first half 2026 financial results and provided a corporate update.

Pascal Prigent, CEO of GENFIT, commented: “We are pleased with the progress across our businesses and believe we now have a strong platform to build upon. Iqirvo® continues to perform above expectations, with royalty revenue more than tripling in the first half of 2026 compared with the same period last year. This momentum could be further supported by the very encouraging ELSPIRE Phase 3 results and is reflected in Ipsen’s recent increase in its peak-sales guidance to €1 billion. At the same time, our MASH diagnostics business is emerging as a potentially significant contributor to future revenues, as the key challenge in this large market is shifting from treatment availability to patient identification and monitoring. Finally, we are starting three distinct Phase 2 studies, with readouts expected next year, each addressing a challenging condition where we believe our programs have the potential to make a meaningful difference.”

I. Financial update

Cash and cash equivalents

As of June 30, 2026, the Company’s cash and cash equivalents amounted to €113.8 million compared with €101.1 million as of December 31, 2025.

In 2026, cash consumption was primarily driven by research and development activities across our Acute-on-Chronic Liver Failure (ACLF) franchise programs, notably NTZ/G1090N, SRT-015, CLM-022 and VS-02 HE, as well as our GNS561 program in cholangiocarcinoma (CCA). This cash consumption was offset by two significant cash inflows during the first half of 2026: (i) the second €30.0 million tranche received under the royalty financing agreement and (ii) the receipt of the first commercial milestone payment of €17.0 million from Ipsen (USD$20.0 million), which had already accrued for in 2025 and received in 2026..

We expect that our existing cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements beyond the end of 2028, enabling the Company to further develop its R&D pipeline and support general corporate purposes. This is based on current assumptions and programs and does not include exceptional events. This estimation assumes (i) our expectation to receive significant future commercial milestone revenue pursuant to the Ipsen Agreement and Ipsen meeting its sales-based thresholds and (ii) drawing down the third and final, optional installment under the Royalty Financing agreement.

Financial highlights

The table below presents the condensed Consolidated Statement of Operations under International Financial Reporting Standards (IFRS) for the first half of 2026, with comparative figures for the first half of 2025.

	Half-year ended
(in € thousands, except earnings per share data)	2025/06/30	2026/06/30
Revenues and other income
Revenue	33,488	21,073
Other income	2,182	3,960
Revenues and other income	35,670	25,033
Operating expenses and other operating income (expenses)
Research and development expenses	(25,117)	(24,927)
General and administrative expenses	(9,971)	(8,328)
Marketing and market access expenses	(392)	(15)
Other operating expenses	(115)	(487)
Operating income (loss)	76	(8,724)
Financial income	1,850	1,463
Financial expenses	(12,027)	(18,854)
Financial profit (loss)	(10,178)	(17,392)
Net profit (loss) before tax	(10,102)	(26,116)
Income tax benefit (expense)	146	(5)
Net profit (loss)	(9,956)	(26,120)
Basic and diluted earnings (loss) per share
Basic earnings (loss) per share (€/share)	(0.20)	(0.52)
Diluted earnings (loss) per share (€/share)	(0.20)	(0.52)

The Group’s condensed statement of financial position, condensed statement of net income and condensed statement of cash flows, prepared in accordance with IFRS accounting standards, are presented in the Appendix of this document.

Detailed information on the condensed consolidated financial statements, together with the statutory auditors’ review report, is provided in the 2026 Half-Year Business and Financial Report, available in the “Investors” section of GENFIT’s website.

We encourage investors to take into consideration all the information presented in our 2025 Universal Registration Document filed under D.26-0221 with the French Autorité des Marchés Financiers (AMF) on April 3, 2026 and the 2026 Half-Year Business and Financial Report before deciding to invest in Company shares; these documents are available on GENFIT’s website: www.genfit.com and on the website of the AMF (www.amf-france.org). This includes, in particular, the risk factors described in section 2 of the 2025 Universal Registration Document, as well as the update provided in section 2.5 of the 2026 Half-Year Business and Financial Report, of which the realization may have (or has had in some cases) material adverse effect on the Group and its activity, financial situation, results, development or perspectives, and which are of importance in the investment decision-making process.

Financial highlight comments

Revenue

Revenue	Half-year ended
(In € thousands)	30/06/2025	30/06/2026
Royalty revenue	6,871	20,975
Milestone revenue	26,556	0
Other revenue	61	98
TOTAL	33,488	21,073

Royalty revenue
Virtually all royalty revenue is derived from worldwide sales of Ipsen’s Iqirvo¹ (elafibranor) under the Ipsen Agreement. These are utilized to repay the Group’s Royalty Financing agreement.

Milestone revenue
On May 20, 2025, GENFIT announced that Ipsen’s Iqirvo (elafibranor) was granted pricing and reimbursement in Italy for PBC, the third major European country to do so in addition to the UK and Germany. This third approval triggered a new milestone payment of €26.5 million under GENFIT’s Licensing and Collaboration Agreement with Ipsen, due upon pricing and reimbursement of Iqirvo (elafibranor) in three major European markets.

When comparing total revenues year on year, the timing of milestone payments should be kept in mind: revenues in the first half of 2025 included a milestone payment, whereas no milestone revenue was recognized in the first half of 2026. Additional milestone payments may, however, be recognized in the future.

Other income

Other income	Half-year ended
(in € thousands)	06/30/2025	06/30/2026
CIR tax credit	2,030	3,091
Other operating income (including exchange gains on trade payables and receivables)	135	854
Government grants and subsidies	17	15
TOTAL	2,182	3,960

The increase in the CIR research tax credit compared to the prior period was primarily driven by an increase in eligible research and development expenses.

Operating expenses

Operating expenses amounted to €33.8 million in 2026, compared with €35.6 million in 2025, and comprised research and development expenses, general and administrative expenses, marketing and pre-commercialization expenses, and other operating income and expenses.

Research and development expenses decreased in 2026 compared with the prior period, primarily as a result of the discontinuation of the VS-01-ACLF program in 2025. This decrease was partially offset by the advancement of development activities across the Group’s other priority programs, notably nitazoxanide (NTZ), VS-02-HE, GNS561 and VS-01-UCD.

General and administrative expenses decreased in 2026 compared with the prior period, primarily due to the non-recurrence of costs related to the liquidation of Versantis recognized in 2025, as well as cost savings resulting from the Company’s delisting from the Nasdaq.

Financial results

The Group recorded a financial loss of €17.4 million in the first half of 2026, compared with a financial loss of €10.2 million in the first half of 2025.

Financial expenses increased in 2026 compared with the prior period, primarily due to changes in the fair value of the royalty financing liability recognized in profit or loss.

Net loss

The first half of 2026 resulted in a net loss of €26.1 million, compared with a net loss of €10.0 million in the first half of 2025.

II. Business update

Two emerging revenue streams

• Elafibranor in cholestatic liver diseases

PBC – On July 30, 2026 Ipsen reported its Iqirvo (elafibranor) sales results for the first half of 2026. Ipsen upgraded its peak sales estimates from €500 million to €1 billion in Primary Biliary Cholangitis (PBC). This revision followed Ipsen’s announcement on July 13, 2026, that the primary endpoint of alkaline phosphatase (ALP) normalization had been achieved in 85% of patients treated with Iqirvo (elafibranor), compared with 23% of patients receiving placebo, in the Phase 3 ELSPIRE study. This revision is also explained by accelerated sales growth in the US driven by a higher number of patients, and strong launches across European countries. Iqirvo’s net sales for the first six months of 2026 amounted to €173 million². This momentum also allowed GENFIT to activate, in January 2026, an additional €30 million tranche under GENFIT’s Royalty Financing agreement with HCRx, enhancing financial flexibility without shareholder dilution.
PSC – Beyond PBC, Ipsen announced the initiation of the Phase 3 ELASCOPE study evaluating elafibranor in Primary Sclerosing Cholangitis (PSC) in early 2026. The PSC market opportunity is estimated to be comparable in size to the second‑line PBC market. Subject to successful development and regulatory approval of elafibranor in this indication, GENFIT would be eligible to receive additional milestone payments as well as incremental double‑digit royalties. Data readout from the Phase 3 trial is expected around 2031.

• NIS^TM Technology in MASH

Program status – In August 2026, Medicare reimbursement of Labcorp’s NASHnext® test (based on GENFIT’s NIS™ technology) became effective under the Clinical Laboratory Fee Schedule for patients meeting coverage criteria. GENFIT believes broader reimbursement by private payers, if obtained, could support accelerated adoption of its technology over time. Further market expansion could also be supported by a potential future in vitro (IVD) launch, which may facilitate deployment across a wider range of healthcare settings.
Highlights on U.S. Market Potential – Based on intention-to-diagnose data collected across key specialties, increasing disease prevalence, and a staged commercialization strategy spanning Laboratory Developed Tests (LDTs) and In Vitro Diagnostics (IVDs), IQVIA estimates U.S. peak sales of products using GENFIT’s technology could exceed $1.5 billion by 2033, with annual testing volume in the U.S. reaching more than 7 million tests.³
Beyond the United States – In Europe and Asia, GENFIT expects its IVD strategy to play a key role in the future commercialization of its NIS™ technology. Supported by the anticipated expansion of the MASH therapeutic market and the broader accessibility enabled by IVD products, international markets could represent a meaningful additional revenue opportunity over time.

R&D pipeline

• Clinical stage: Three programs entering Phase 2 clinical development in the second half of 2026

Two assets in Acute on-Chronic Liver Failure (ACLF)
Nangibotide – In summer 2026, GENFIT acquired nangibotide, a differentiated late-stage asset, reinforcing the Company’s portfolio of innovative therapies addressing high unmet medical needs. The investigation in Phase 2 is supported by a robust scientific and clinical foundation around the TREM-1 pathway and the asset’s profile:

• Strong knowledge of nangibotide’s biological pathway
• Multiple efficacy signals already observed with nangibotide in post-hoc analyses of three Phase 2 clinical trials in septic shock and COVID-19 subjects, including a statistically significant reduction in mortality in severe COVID-19 and significant improvements in SOFA score from baseline in septic shock
• Overall favorable safety and tolerability profile demonstrated across four clinical trials, with more than 400 subjects exposed to nangibotide, and no meaningful differences versus placebo in safety outcomes

Nangibotide is expected to enter a Phase 2 study in ACLF in the fourth quarter of 2026, with data readout targeted in 2027.
Nitazoxanide (NTZ) – Positive Phase 1 data reported in early 2026 confirmed the favorable safety profile of NTZ and demonstrated multi‑modal biological activity, supporting its continued clinical development across the ACLF disease continuum. In March 2026, NTZ was granted Orphan Drug Designation for the treatment of ACLF. A proof‑of‑concept study was initiated in the third quarter of 2026, with data expected in 2027.

One asset in oncology
GNS561 – Encouraging preliminary data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated CCA were disclosed in December 2025 and June 2026. This Phase 1b dose escalation is progressing as planned, with additional data anticipated in the second half of 2026, following study expansion into additional cohorts supported by preliminary signals. The Phase 2 initiation is on track for launch in the second semester of 2026. Phase 2 data readout is targeted in 2027.

• Research stage: multiple targets in ACLF and oncology

ACLF – GENFIT’s strategy for the treatment of ACLF is concentrated around its two most advanced assets, nangibotide and NTZ, both entering Phase 2 clinical investigations in 2026, as well as the potential of extracellular vesicle-based approaches. This focus is underpinned by robust body of evidence generated through internal preclinical research, external datasets, translational analyses, and ongoing interactions with leading international hepatology and critical care experts. GENFIT is thus directing its capital and development resources towards the programs with the strongest translational rationale and clinical potential, and has discontinued the development of SRT-015 and CLM-022 programs. The evaluation of the VS-02-HE program remains ongoing, alongside continued exploration of additional mechanisms of action relevant to ACLF. Further updates will be provided as these programs mature and progress toward clinical development.

Oncology – Following the encouraging preliminary results observed with GNS561 in combination with a MEK inhibitor in cholangiocarcinoma (CCA), further supporting the therapeutic potential of autophagy inhibition, GENFIT has initiated research activities to explore this approach in additional oncology indications and in combination with other therapeutic agents. Further details will be provided as and when these programs advance into clinical development.

Corporate governance updates

In February 2026, Mr. John BROZEK replaced Ms. Florence SÉJOURNÉ as permanent representative of Biotech Avenir SAS on the Company’s Board of Directors.

Extra-financial performance

In May 2026 GENFIT published its annual Extra-Financial Performance Report (fiscal year 2025), highlighting its latest initiatives and providing insights on the evolution of key performance indicators. In terms of recognition, GENFIT maintained its “Prime status” with ISS ESG and gold medal awarded by Ethifinance in recognition of its ESG performance. GENFIT is also a Certified B Corporation since 2025.

	Half-year Consolidated Financial Results at June 30, 2026

The Condensed Consolidated Statements of Financial Position, Statements of Operations and Statements of Cash Flow of the Group were prepared in accordance with the IFRS.

The limited review procedures on the condensed consolidated financial statements have been performed. The half-year consolidated financial statements for the period ended June 30, 2026 were approved by the Board of Directors on September 28, 2026.

The condensed consolidated financial statements as well as the notes to the consolidated financial statements for the period ended June 30, 2026 and the statutory auditor’s report on the consolidated financial statements are included in the Half Year Business and Financial Report at June 30, 2026 available on the “Investors” page of the GENFIT website.

All financial information (unless indicated otherwise) is presented in thousands of euros (€).

Condensed Consolidated Statement of Financial Position

Assets

	As of
(in € thousands)	2025/12/31	2026/06/30
Current assets
Cash and cash equivalents	101,093	113,822
Current trade and other receivables	40,328	24,776
Other current assets	2,857	2,813
Inventories	4	4
Total – Current assets	144,282	141,416
Non-current assets
Intangible assets	4,155	2,102
Property, plant and equipment	7,100	6,674
Other non-current financial assets	3,503	3,375
Deferred tax assets	0	0
Total – Non-current assets	14,759	12,151
Total – Assets	159,041	153,567

Shareholders’ equity and liabilities

	As of
(in € thousands)	2025/12/31	2026/06/30
Current liabilities
Current convertible loans	0	0
Other current loans and borrowings	2,025	2,020
Current trade and other payables	26,392	19,192
Current provisions	2,958	2,052
Other current tax liabilities	0	0
Total – Current liabilities	72,312	89,251
Non-current liabilities
Other non-current loans and borrowings	3,546	2,535
Non-current employee benefits	1,475	1,580
Deferred tax liabilities	0	0
Total – Non-current liabilities	109,265	112,852
Shareholders’ equity
Share capital	12,509	12,524
Share premium	440,303	440,930
Retained earnings (accumulated deficit)	(389,813)	(475,908)
Currency translation adjustment	433	38
Net profit (loss)	(85,968)	(26,120)
Total – Shareholders’ equity	(22,536)	(48,536)
Total – Shareholders’ equity & liabilities	159,041	153,567

Condensed Consolidated Statement of Operations

	Half-year ended
(in € thousands, except earnings per share data)	2025/06/30	2026/06/30
Revenues and other income
Revenue	33,488	21,073
Other income	2,182	3,960
Revenues and other income	35,670	25,033
Operating expenses and other operating income (expenses)
Research and development expenses	(25,117)	(24,927)
General and administrative expenses	(9,971)	(8,328)
Marketing and market access expenses	(392)	(15)
Other operating expenses	(115)	(487)
Operating income (loss)	76	(8,724)
Financial income	1,850	1,463
Financial expenses	(12,027)	(18,854)
Financial profit (loss)	(10,178)	(17,392)
Net profit (loss) before tax	(10,102)	(26,116)
Income tax benefit (expense)	146	(5)
Net profit (loss)	(9,956)	(26,120)
Basic and diluted earnings (loss) per share
Basic earnings (loss) per share (€/share)	(0.20)	(0.52)
Diluted earnings (loss) per share (€/share)	(0.20)	(0.52)

Condensed Statement of Cash Flows

	Half-year ended	Half-year ended
(in € thousands)	2025/06/30	2026/06/30
Cash flows from operating activities
+ Net profit (loss)	(9,956)	(26,118)
Reconciliation of net loss to net cash used in operating activities
Adjustments for:
+ Depreciation and amortization on tangible and intangible assets	897	943
+ Impairment and provisions	193	2,238
+ Expenses related to share-based compensation	242	485
– Loss (gain) on disposal of property, plant and equipment	(12)	0
+ Net finance expenses (revenue)	6,324	17,940
+ Income tax expense (benefit)	(146)	5
+ Other non-cash items	590	(11)
Operating cash flows before change in working capital	(1,868)	(4,518)
Decrease (increase) in trade receivables and other assets	(37,840)	14,190
(Decrease) increase in trade payables and other liabilities	9,606	(6,714)
Change in working capital	(28,234)	7,476
Income tax paid	0	0
Net cash flows provided by (used in) in operating activities	(30,102)	2,958
Cash flows from investment activities
– Acquisition of other intangible assets	(2,034)	(6)
– Acquisition of property, plant and equipment	(1,054)	(537)
+ Proceeds from disposal of / reimbursement of property, plant and equipment	39	0
– Acquisition of financial instruments	(170)	(37)
+ Proceeds from sale of financial instruments	0	22
Net cash flows provided by (used in ) investment activities	(3,219)	(557)
Cash flows from financing activities
+ Proceeds from issue of share capital (net)	17	154
+ Proceeds from new loans and borrowings	130,020	30,000
– Repayments of loans and borrowings	(62,105)	(431)
– Repayments of royalty financing liability	(4,492)	(18,723)
– Payments of debt issuance costs	(3,363)	(375)
– Payments on lease debts	(555)	(586)
– Financial interests paid (including finance lease)	(530)	(34)
+ Financial interests received	295	429
Net cash flows provided by (used in ) financing activities	59,287	10,435
Increase (decrease) in cash and cash equivalents	25,966	12,835
Cash and cash equivalents at the beginning of the period	81,788	101,093
Effects of exchange rate changes on cash	(243)	(106)
Cash and cash equivalents at the end of the period	107,511	113,822

ABOUT GENFIT

GENFIT is a biopharmaceutical company committed to improving the lives of patients with rare, life-threatening liver diseases whose medical needs remain largely unmet. GENFIT is a pioneer in liver disease research and development with a rich history and a solid scientific heritage spanning more than two decades. Today, GENFIT focuses on Acute on-chronic Liver Failure (ACLF) and associated conditions such as acute decompensation (AD) and hepatic encephalopathy (HE). It develops therapeutic assets which have complementary mechanisms of action, selected to address key pathophysiological pathways. GENFIT also targets other serious diseases, such as cholangiocarcinoma (CCA), urea cycle disorders (UCD) and organic acidemia (OA). Its R&D portfolio, covering several stages of development, ensures a constant news flow. GENFIT’s expertise in developing high-potential molecules – from early to advanced pre-commercialization stages – culminated in 2024 with the accelerated approval of Iqirvo® (elafibranor) by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA) and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom for second-line treatment of Primary Biliary Cholangitis (PBC). Iqirvo® is now marketed in several countries.⁴ Beyond therapies, GENFIT also has a diagnostic franchise including NIS2+® for the detection of Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as NASH for non-alcoholic steatohepatitis). GENFIT, a BCorp™ certified company since 2025, is headquartered in Lille, France and has offices in Paris (France) and Cambridge, MA (USA). The Company is listed on the Euronext regulated market in Paris, Compartment B (Euronext: GNFT) and joined the CAC Mid 60 and SBF 120 indices on September 18, 2026. In 2021, Ipsen became one of GENFIT’s largest shareholders, acquiring an 8% stake in the Company’s capital. www.genfit.com

FORWARD LOOKING STATEMENTS

This press release contains certain forward-looking statements with respect to GENFIT, including, but not limited to, statements relating to the sales trajectory and future commercial performance of Iqirvo® in PBC, elafibranor’s ability to be successfully developed and subsequently approved in PSC, and the size of the market opportunity that PSC may represent; the possibility of receiving future milestone payments and royalties under its license agreement with Ipsen; relating to the future development of its NIS™ technologies in MASH diagnosis and the size of the market opportunity that MASH may represent, including the development and regulatory approval of new MASH therapies and their commercial adoption and rollout; the adoption of NASHnext® as a diagnostic test to identify patients with at-risk MASH and the size of this patient population; reimbursement of the test by private payors; the Company’s ability to establish partnerships with major pharmaceutical companies commercializing such therapies; its ability to develop an IVD (In Vitro Diagnostic) version of a diagnostic test based on these technologies; and the possibility of receiving future revenues under its license agreement with Labcorp; relating to the future development of the GNS561/trametinib combination and the anticipated timelines for obtaining additional Phase 1b results, initiating Phase 2 of the ongoing Phase 1b/2 clinical trial in CCA, and obtaining the results thereof, as well as the potential of GNS561 in combination with other treatments and/or in other cancer indications; relating to the future development of NTZ/G1090N in ACLF, including the significance and implications of NTZ’s FDA Orphan Drug Designation (ODD), the initiation of a Phase 2 clinical trial under the NTZ/G1090N program, and the anticipated timelines for obtaining its results; relating to the future development of nangibotide, including the potential relevance on future clinical investigations of efficacy signals and safety data observed in prior clinical studies conducted in other indications, as well as the Company’s ability to initiate a Phase 2 program with this drug candidate in this indication and the anticipated timelines for such initiation and the availability of results; relating to the objectives of its portfolio management strategy; and, more generally, forward-looking statements regarding its financial position, the expected progress of its research and development programs, and their potential therapeutic benefits in the indications for which they are intended. The use of certain words, such as “believe”, “potential”, “expect”, “target”, “may”, “will”, “should”, “could”, “if” and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on the current expectations and reasonable assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among others, the uncertainties inherent in research and development, including in relation to non-clinical and pre-clinical programs, reproducibility of preclinical results, the translation of animal model data to human biology, in relation to safety of drug candidates, cost of, progression of, and results from, our ongoing and planned clinical trials, patient recruitment, review and approvals by regulatory authorities in the United States, Europe and worldwide, of our drug and diagnostic candidates, pricing, approval and commercial success of elafibranor in the relevant jurisdictions, exchange rate fluctuations, and our continued ability to raise capital to fund our development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Risk Factors and Internal Control” of the Company’s 2025 Universal Registration Document filed on April 3, 2026 (no. 26-0221) with the Autorité des marchés financiers (“AMF”), which is available on GENFIT’s website (www.genfit.fr) and the AMF’s website (www.amf.org), and those discussed in reports filed with the AMF or otherwise made public, by the Company. In addition, even if the results, performance, financial position and liquidity of the Company and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this press release. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise.

CONTACTS

GENFIT | Investors
Jean-Christophe Marcoux – Chief Corporate Affairs Officer | Tel : + 33 3 20 16 40 00 | jean-christophe.marcoux@genfit.com

Kevin Gardner – Life Science Advisors | kgardner@lifesciadvisors.com

GENFIT | Media
Bruno ARABIAN – Agence Maarc | Tel : 06 87 88 47 26 | bruno.arabian@maarc.fr

Stephanie BOYER | Tel : + 33 3 20 16 40 00 | stephanie.boyer@genfit.com

GENFIT | 885 Avenue Eugène Avinée, 59120 Loos – FRANCE | +333 2016 4000 | www.genfit.com

---

1 Iqirvo® is a registered trademark of GENFIT SA

2 https://www.ipsen.com/wp-content/uploads/2026/07/Ipsen-PR_HY-2026_30072026.pdf

3 Regulatory authorization through the applicable local approval process is required for IVD products and has not yet been obtained.

4 Elafibranor is marketed and commercialized, notably in the U.S and Europe, by Ipsen under the trademark Iqirvo®

Attachment

• GENFIT Reports First-Half 2026 Financial Results and Provides Corporate Update

HONG KONG, Sept. 28, 2026 (GLOBE NEWSWIRE) — Masonglory Limited (the “Company”) (Nasdaq: MSGY), a subcontractor providing wet trades services and other ancillary services in Hong Kong, today announced that on September 25, 2026, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”) with four investors (collectively, the “Purchasers”), pursuant to which the Purchasers agreed to purchase from the Company, in a private placement (the “Private Placement”), an aggregate of 667,000 Class A ordinary shares of the Company, par value US$0.0008 each (the “Class A Ordinary Shares”), at a purchase price of US$1.50 per share, for aggregate gross proceeds to the Company of approximately US$1.0 million (US$1,000,500), before deducting offering expenses.

In addition, for no additional consideration, each Purchaser will receive at the closing of the Private Placement a Series A warrant to purchase up to 166,750 Class A Ordinary Shares at an exercise price of US$1.30 per share and a Series B warrant to purchase up to 166,750 Class A Ordinary Shares at an exercise price of US$1.10 per share (collectively, the “Warrants”). The Warrants are exercisable from the date of issuance and have a term of two years from the date of issuance.

The Company expects to complete the closing of the transactions contemplated by the Securities Purchase Agreement as soon as practicable, subject to the satisfaction of customary closing conditions, and to issue the Class A Ordinary Shares and the Warrants to the Purchasers at the closing.

The Company intends to use the net proceeds from the Private Placement to fund the continued acquisition of equity interests in Beta Beteiligungs und Besitz GmbH, a private limited liability company organized under the laws of the Republic of Austria (the “Target”), which is engaged in the trading and distribution of construction materials, principally bathtubs, hot tubs and swim spas, in Continental Europe. As previously announced on August 13, 2026, the Company entered into a share swap agreement on August 12, 2026 to acquire a 20% equity interest in the Target. The specific percentage of additional equity interests in the Target to be acquired and the consideration therefor are still under negotiation between the Company and the Target, and no definitive agreement in respect thereof has been entered into as of the date of this press release. The Company will make further announcement(s) in respect of the foregoing as and when appropriate.

The Class A Ordinary Shares to be issued in the Private Placement, the Warrants and the Class A Ordinary Shares issuable upon exercise of the Warrants have been and will be issued and sold in an offshore transaction without registration under the Securities Act of 1933, as amended, in reliance on applicable exemptions from registration, and will constitute “restricted securities”. Each Purchaser has represented to the Company that it is not affiliated with the Company or any of its directors or officers. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Masonglory Limited

Founded in 2018 in Hong Kong, Masonglory Limited is a subcontractor providing wet trades services and other ancillary services to property developers and Hong Kong government. As a registered specialist trade contractor (plastering-group 2) since 2020, the Company provides customers with comprehensive wet trades works solutions, which principally include: (i) plastering on floors, ceilings, and walls; (ii) tile laying on internal and external walls and floors; (iii) brick laying; (iv) floor screeding; and (v) marble works. For more information, please visit: https://www.masontech.com.hk/; https://ir.masontech.com.hk/

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “aim”, “anticipate”, “believe”, “estimate”, “expect”, “going forward”, “intend”, “may”, “plan”, “potential”, “predict”, “propose”, “seek”, “should”, “will”, “would” or other similar expressions in this press release. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

Masonglory Limited

Investor Relations Department

Email: services@wealthfsllc.com